Oncology Institute (TOI) Stock Price, News & Analysis

Company Overview

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Key Stats

• Today's Range: $3.05 to $3.42
• 50-Day Range: $2.05 to $4.28
• 52-Week Range: $0.13 to $4.50
• Volume: 3.93 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $308.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Oncology Institute Stock Analysis - MarketRank™

Oncology Institute scored higher than 37% of companies evaluated by MarketBeat, and ranked 752nd out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Oncology Institute has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Oncology Institute has a consensus price target of $7.00, representing about 112.1% upside from its current price of $3.30.

Amount of Analyst Coverage

Oncology Institute has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncology Institute is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncology Institute is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oncology Institute has a P/B Ratio of 66.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.53% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncology Institute has recently increased by 13.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncology Institute does not currently pay a dividend.

Dividend Growth

Oncology Institute does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.53% of the float of Oncology Institute has been sold short.

Short Interest Ratio / Days to Cover

Oncology Institute has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncology Institute has recently increased by 13.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: -0.58

News Sentiment

Oncology Institute has a news sentiment score of -0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Oncology Institute this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for TOI on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.

MarketBeat Follows

19 people have added Oncology Institute to their MarketBeat watchlist in the last 30 days. This is an increase of 111% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oncology Institute insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,703,000.00 in company stock.

Percentage Held by Insiders

Only 8.50% of the stock of Oncology Institute is held by insiders.

Percentage Held by Institutions

Only 36.86% of the stock of Oncology Institute is held by institutions.

TOI Stock Analysis - Frequently Asked Questions

How have TOI shares performed this year?

Oncology Institute's stock was trading at $0.3090 at the start of the year. Since then, TOI stock has increased by 968.0% and is now trading at $3.30.

How were Oncology Institute's earnings last quarter?

The Oncology Institute, Inc. (NASDAQ:TOI) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The company had revenue of $104.41 million for the quarter. Oncology Institute had a negative net margin of 14.26% and a negative trailing twelve-month return on equity of 1,527.21%.
Read the conference call transcript.

Who are Oncology Institute's major shareholders?

Top institutional shareholders of Oncology Institute include Tiff Advisory Services LLC (4.07%), Balyasny Asset Management L.P. (2.82%), Marshall Wace LLP (1.66%) and Geode Capital Management LLC (1.43%). Insiders that own company stock include Growth I LP M33, Daniel Virnich, Brad Hively, Richard A Barasch, Mark L Pacala, Matthew P Miller, Yale Podnos, Mohit Kaushal and Havencrest Healthcare Partners.
View institutional ownership trends.

How do I buy shares of Oncology Institute?

Shares of TOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncology Institute own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncology Institute investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 9/07/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:TOI
• CIK: 1799191
• Web: theoncologyinstitute.com
• Phone: 562-735-3226
• Fax: N/A
• Employees: 660
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oncology Institute: $7.00
• High Price Target: $8.00
• Low Price Target: $6.00
• Potential Upside/Downside: +112.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.66 million
• Net Margins: -14.26%
• Pretax Margin: -15.56%
• Return on Equity: -1,527.21%
• Return on Assets: -34.25%

Debt

• Debt-to-Equity Ratio: 14.58
• Current Ratio: 1.62
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $393.41 million
• Price / Sales: 0.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.05 per share
• Price / Book: 66.00

Miscellaneous

• Outstanding Shares: 93,500,000
• Free Float: 85,557,000
• Market Cap: $308.55 million
• Optionable: Not Optionable
• Beta: 0.10